C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 162,880 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on August 10, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee’s start date, with the remainder of the shares vesting in thirty-six equal monthly installments thereafter, subject to the employee’s continued employment with C4T through each vesting date.